GP Vivas · metabolic-and-endocrine-health
MASLD — structured viva
Structured oral on MASLD: the CVD-first framing, the two-step pathway, the FIB-4 traps, and the new pharmacotherapy era.
On this page
Study tools
Target exams
RACGP CCEFRACGP oralsMRCGP SCA
Prompt
The examiner opens: 'A patient with fatty liver on ultrasound asks what it means for her heart. Answer that, then tell me who else in your practice you should be scanning.' The viva branches through cardiovascular risk, the pathway, FIB-4 traps, treatment and screening.
Stem
You are the GP. The examiner probes the cardiovascular framing, then the pathway. [15]
References11ShowHide
- [1]Sung S, Al-Karaghouli M, Tam M et al. Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care. Hepatol Commun, 2025.PMID 39670870
- [2]Adams LA, Thiele M, Tsochatzis EA Detecting at-risk steatotic liver disease and liver fibrosis in the community. Hepatology, 2025.PMID 40384127
- [3]Petta S, Kim K, Targher G et al. Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. Liver Int, 2025.PMID 41144918
- [4]Bansal MB, Patton H, Morgan TR et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology, 2026.PMID 41201884
- [7]Shaheen AA, Baguley E, Swain MG et al. Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways. JHEP Rep, 2026.PMID 41810425
- [9]Younossi ZM, Kalligeros M, Wong VW et al. Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Gastroenterol Hepatol, 2026.PMID 41950980
- [10]Driessen S, van Son KC, Riemersma TR et al. Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study. Hepatol Commun, 2026.PMID 42275588
- [11]Mantovani A, Morandin R, Rolli N et al. Bidirectional relationship between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus. EXCLI J, 2026.PMID 42376436
- [12]Singhai A, Meena R, Joshi R et al. Prevalence of metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus in India: A systematic review and meta-analysis. Indian J Med Res, 2026.PMID 42397829
- [15]Li S, Toutoungy M, Patel J et al. MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice. Curr Hypertens Rep, 2026.PMID 42541628
- [16]Adinolfi LE, Marrone A, Izzi A et al. Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues. Expert Rev Endocrinol Metab, 2026.PMID 42552573